ENGELBERG CENTER for
Health Care Reform
at BROOKINGS

New Policy Directions for Biomedical Innovation
The Brookings Institution • Washington, DC
Monday, November 19, 2012

Biographies

Christopher Austin, MD, is director of the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health (NIH). NCATS' mission is to catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Before becoming NCATS director in September 2012, he was director of the NCATS Division of Preclinical Innovation, which focuses on translating basic science discoveries into new treatments, particularly for rare and neglected diseases, and developing new technologies and paradigms to improve the efficiency of therapeutic and diagnostic development. In this role, he founded and directed numerous initiatives including the NIH Chemical Genomics Center (NCGC), the Therapeutics for Rare and Neglected Diseases (TRND) program, and the Toxicology in the 21st Century (Tox21) program. Before joining NIH in 2002, Dr. Austin directed research programs, genomics-based target discovery, pharmacogenomics, and neuropsychiatric drug development at Merck, with a particular focus on schizophrenia. Dr. Austin received his AB in biology from Princeton University and MD from Harvard Medical School. He completed clinical training in internal medicine and neurology at Massachusetts General Hospital, and a fellowship in genetics at Harvard University.

Deborah W. Brooks, MBA, MS, is co-founder and executive vice chairman of The Michael J. Fox Foundation for Parkinson's Research (MJFF). Ms. Brooks launched MJFF with Michael J. Fox and served as the Foundation's president and chief executive officer from October 2000 to February 2007. With a background in business and finance, she brings strategic leadership, business acumen and an entrepreneurial approach to the Foundation, which has grown rapidly from a start-up to the world's largest private funder of Parkinson's disease research. Ms. Brooks oversees the foundation's fundraising, communications and digital strategy teams, serving as a senior adviser on strategic and programmatic direction. Ms. Brooks serves on several boards, including the advisory board for FasterCures' Philanthropy Advisory Service and the board of overseers of the School of Social Policy and Practice at the University of Pennsylvania. Additionally, she serves on the MBA Advisory Board of the Tuck School of Business at Dartmouth University and the Advisory Board for Women in Business at Tuck. She is a past member of the Parkinson's Institute Board of Directors, Pfizer's U.S. Health Advisory Board, the National Advisory Environmental Health Sciences Council of the National Institutes of Health, and External Advisory Board for Emory University's Collaborative Center for Parkinson's Disease Environmental Research. She is also a past director of the Parkinson's Action Network. Ms. Brooks started her career at Goldman, Sachs & Co., where she spent nine years as vice-president in the Fixed Income and Asset Management Divisions. She holds an AB in economics from the College of William and Mary, an MBA from the Tuck School at Dartmouth College and an MS in marital and family therapy from Northwestern University.

Robert Conley, MD, is the regulatory leader for biomedicines at Eli Lilly and Company and Distinguished Lilly Scholar in neuroscience. He leads the late-phase regulatory group responsible for psychiatry, neurology, cardiology, urology, men's health, bone/muscle/joint disorders and autoimmune disorders, as well as advising on all phases of neuroscience development. He was, until 2008, the chief of treatment research at the Maryland Psychiatric Research Center. His current research work focuses on the basic understanding of the neuroanatomy and physiology associated with severe mental illness, and the health outcomes of people with severe mental illness. He has been the principal investigator of studies sponsored by the National Institute of Mental Health, the National Institute on Drug Abuse, the Stanley Research Foundation and The National Alliance for Research in Schizophrenia and Affective Disorders. He is the past Chairman of the Institutional Review Board for the National Institute on Drug Abuse and also the University of Maryland, Baltimore and is now a lead member of the Bioethics Advisory Committee at Lilly. Dr. Conley has authored over 200 publications in journals such as the *Journal of Psychopharmacology*, the *American Journal of Psychiatry*, *Archives of General Psychiatry*, *Schizophrenia Research*, and the *Journal of Clinical Psychopharmacology*. He is the founding editor of *Clinical Schizophrenia & Related Psychoses*.

Mark McClellan, MD, PhD, is director of the Engelberg Center for Health Care Reform and Leonard D. Schaeffer Chair in Health Policy Studies at the Brookings Institution. At the Center, his work focuses on promoting high-quality, innovative and affordable health care. A doctor and economist by training, he also has a highly distinguished record in public service and in academic research. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the U.S. Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy. These include the Medicare prescription drug benefit, the FDA's Critical Path Initiative, and public-private initiatives to develop better information on the quality and cost of care. Dr. McClellan chairs the FDA's Reagan-Udall Foundation, is co-chair of the Quality Alliance Steering Committee, sits on the National Quality Forum's Board of Directors, is a member of the Institute of Medicine, and is a research associate at the National Bureau of Economic Research. He previously served as a member of the President's Council of Economic Advisers and senior director for health care policy at the White House, and was an associate professor of economics and medicine at Stanford University.

John Mendelsohn, MD, is the director of the Khalifa Institute for Personalized Cancer Therapy at the University of Texas' MD Anderson Cancer Center in Houston, Texas. He was president of MD Anderson from 1996 until 2011. Under his direction, MD Anderson assumed a leadership role in translational and clinical cancer research, and was named the top cancer hospital in the United States eight of the past ten years in *U.S. News & World Report's* "America's Best Hospitals" survey. Previously, he chaired the Department of Medicine at Memorial Sloan-Kettering Cancer Center, and he began his career at the University of California, San Diego, where he was founding director of its cancer center. Dr. Mendelsohn and his collaborators pioneered the concept of cancer therapy targeting the products of genes that cause cancer, and targeting a receptor tyrosine kinase. His team's innovative research on inhibition of the epidermal growth factor (EGF) receptor tyrosine kinase led to production and investigation of monoclonal antibody C225 (Erbitux), which is FDA-approved for colon cancer and head and neck cancer. He served as founding editor-in-chief of *Clinical Cancer Research*, has published over 250 articles and reviews, and has received many prizes and awards. Dr. Mendelsohn is chairman of the Institute of Medicine's National Cancer Policy Forum. He has directed postdoctoral programs that trained many dozens of medical oncologists and scientists. He is an active board member of several Houston-area organizations, including Houston Grand Opera, BioHouston and the Center for Houston's Future.

Ed Penhoet, PhD, is director of Alta Partners. He joined Alta in 2000 and has been there full-time since 2008. He is the co-founder of Chiron and served as the company's president and chief executive officer from its formation in 1981 until April 1998. He currently serves on the board of directors of ChemoCentryx, Immune Design, Metabolex, Scynexis and Veloxis Pharmaceuticals. He served as vice-chairman of the governing board of the Independent Citizens Oversight Committee for the California Institute of Regenerative Medicine (CIRM) from 2005 to 2010, and served as the president of the Gordon and Betty Moore Foundation from 2004 to 2008. Dr. Penhoet was recently appointed to President Obama's Council of Advisors on Science and Technology (PCAST), an advisory group comprised of 20 of the nation's leading scientists and engineers who directly advise the President and the Executive Office of the President. For 10 years prior to founding Chiron, Dr. Penhoet was a faculty member in the biochemistry department of the University of California, Berkeley. Dr. Penhoet is the immediate past dean of the School of Public Health at the University of California, Berkeley. He is a member of both the Institute of Medicine of the National Academies and the American Academy of Arts and Sciences. He has co-authored more than 50 scientific articles and papers.

Earl Steinberg, MD, MPP, is executive vice-president of Innovation and Dissemination and chief of the Healthcare Solutions Enterprise at the Geisinger Health System. Prior to joining Geisinger, Dr. Steinberg, was senior vice president for Clinical Strategy, Quality & Outcomes at WellPoint, Inc., the largest commercial health insurer by membership in the U.S., and president and chief executive officer of Resolution Health Inc. (RHI), a leading health care data analysis company that provides innovative quality improvement and cost reduction services to health plans, employers, pharmacy benefit management (PBM) and disease management companies. Dr. Steinberg also is an adjunct professor of Medicine and of Health Policy and Management at Johns Hopkins University, a member of Blue Cross/Blue Shield Association's National Medical Advisory Panel, and was co-chair of the Institute of Medicine's panel on Standards for Development of Trustworthy Practice Guidelines. Prior to joining RHI, Dr. Steinberg spent six years as vice president of Covance Health Economics and Outcomes Services Inc., director of its Quality Assessment and Improvement Systems (QAIS) Division, and co-director of its Outcomes Studies Group (OSG). He spent twelve years on the full-time faculty at Johns Hopkins University, where he was Professor of Medicine and of Health Policy and Management and director of The Johns Hopkins Program for Medical Technology and Practice Assessment; and four years on the Federal Physician Payment Review Commission (PPRC). Dr. Steinberg received his AB degree from Harvard College (summa cum laude), his MD from Harvard Medical School, and a Master of Public Policy degree from the Kennedy School of Government. His residency training in internal medicine was performed at Massachusetts General Hospital. Dr. Steinberg has received numerous awards, including the Henry J. Kaiser Family Foundation Faculty Scholar Award in General Internal Medicine (1984), the "Outstanding Young Investigator" Award from the Association for Health Services Research (1988), and a Special Presidential Visionary Award from the National Kidney Foundation (2004) for his work as the scientific director of the NKF's landmark Kidney Disease Outcomes and Quality Initiative, which produced over 250 clinical practice guidelines for management of patients with end stage renal disease. He also is a Fellow of both the American College of Physicians and AcademyHealth, and has published more than 125 articles in peer reviewed journals.